睿知中国医院研究地图
候选清单

正在招募肝细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由华中科技大学同济医学院附属协和医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07776080,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Child-Pugh class A or B with a Child-Pugh score ≤7.

    入选标准第 5 条

    Child-Pugh score ≥8.

    排除标准第 2 条

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

    入选标准第 9 条

    ECOG performance status ≥2.

    排除标准第 1 条

  4. Evidence of acute or active hepatitis B or hepatitis C infection, including HBV-DNA >2,000 IU/mL or HCV-RNA >1,000 copies/mL.

    排除标准第 11 条

  5. Women of childbearing potential must use effective contraception beginning at least 1 month before screening and throughout the study until the protocol-specified period after study completion.

    入选标准第 12 条

    Pregnancy or breastfeeding.

    排除标准第 12 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;既往治疗;化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07776080,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥18 and ≤75 years at the time of signing informed consent.
  2. Histologically or clinically confirmed hepatocellular carcinoma (HCC) according to the 2024 Chinese Guidelines for the Diagnosis and Treatment of Primary Liver Cancer.
  3. Radiologically confirmed portal vein tumor thrombus (PVTT), classified as Cheng type I-IV.
  4. No prior systemic or local treatment directed at PVTT, including targeted therapy, immunotherapy, or systemic chemotherapy.
  5. Child-Pugh class A or B with a Child-Pugh score ≤7.
  6. Considered unsuitable for curative surgery or liver transplantation after multidisciplinary evaluation, but suitable for radiotherapy.
  7. Adequate organ function, including: WBC ≥3.0 × 10⁹/L; PLT ≥50 × 10⁹/L; hemoglobin ≥80 g/L; ALT ≤5 × ULN; AST ≤5 × ULN; total bilirubin ≤3 × ULN; albumin ≥28 g/L; and creatinine clearance ≥80 mL/min.
  8. At least one measurable lesion according to mRECIST.
  9. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  10. Life expectancy >3 months.
  11. No history of abdominal radiotherapy.
  12. Women of childbearing potential must use effective contraception beginning at least 1 month before screening and throughout the study until the protocol-specified period after study completion.
  13. Willing and able to comply with study follow-up until death, study completion, or study termination.

排除标准:Exclusion Criteria:

  1. ECOG performance status ≥2.
  2. Child-Pugh score ≥8.
  3. Severe dysfunction of major organs, including the heart, liver, or kidneys.
  4. Prior targeted therapy, immunotherapy, radiotherapy, systemic chemotherapy, or other anticancer treatment.
  5. Known hypersensitivity or allergic reaction to any component of the study treatment.
  6. History of organ transplantation or autologous/allogeneic stem cell transplantation.
  7. Currently receiving chronic systemic immunotherapy or hormonal therapy other than physiologic replacement therapy.
  8. Any unstable systemic disease, including active infection; uncontrolled severe hypertension; unstable angina; new-onset angina within the previous 3 months; congestive heart failure of NYHA class II or higher; myocardial infarction within the previous 6 months; severe cardiac arrhythmia requiring medication; gastrointestinal bleeding within the previous 1 month; or active bleeding tendency.
  9. Concurrent other malignancy that has not been cured, except carcinoma in situ at another site.
  10. Any disease, metabolic disorder, physical examination finding, or laboratory abnormality that, in the investigator's judgment, suggests a contraindication to the study treatment or a high risk of treatment-related complications.
  11. Evidence of acute or active hepatitis B or hepatitis C infection, including HBV-DNA >2,000 IU/mL or HCV-RNA >1,000 copies/mL.
  12. Pregnancy or breastfeeding.
  13. Any other unfavorable medical or psychiatric condition that, in the investigator's judgment, may affect protocol compliance or evaluation of study endpoints and makes the participant unsuitable for the study.
  14. Lack of legal capacity or limited legal capacity.
  15. Other contraindications to radiotherapy or targeted/immunotherapy.
  16. Any participant considered unsuitable for enrollment by the investigator.

引自 ClinicalTrials.gov, NCT07776080, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07776080,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07776080